A Novel inhibitor of DNA polymerase β enhances the ability of temozolomide to impair the growth of colon cancer cells

Molecular Cancer Research

Volumn 7, Issue 12, 2009, Pages 1973-1983

  Jaiswal, Aruna S ^a   Banerjee, Sanjeev ^d   Panda, Harekrushna ^a   Bulkin, Charles D ^c   Izumi, Tadahide ^c   Sarkar, Fazlul H ^d   Ostrov, David A ^b   Narayan, Satya ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO N [3 (4 CHLOROANILINO) 1H 1,2,4 TRIAZOL 5 YL] 2 MERCAPTO 5 METHYLBENZENESULFONAMIDE; BENZENESULFONAMIDE DERIVATIVE; DNA DIRECTED DNA POLYMERASE BETA; NSC 666715; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANISOTROPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CLONOGENIC ASSAY; COLON CANCER; COLORECTAL CANCER; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; EXCISION REPAIR; FLUORESCENCE; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DACARBAZINE; DNA LIGASES; DNA MISMATCH REPAIR; DNA POLYMERASE BETA; DNA, NEOPLASM; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; FLAP ENDONUCLEASES; HUMANS; MICE; NUCLEOTIDES; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73849089230     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0309     Document Type: Article

References (45)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2003;2:41.
3. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
4. Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 2009;55:684-97.
5. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
6. Sanchez-Olea R, Calera MR, Degterev A. Molecular pathways involved in cell death after chemically induced DNA damage. EXS 2009;99:209-30.
7. Ding J, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA repair systems. Trends Pharmacol Sci 2006;27:338-44.
8. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 2004;5: 623-7.
9. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, Roy R. Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 2008;8:351-7.
10. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006;12:328-31.
11. Kaina B, Ochs K, Grosch S, et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog Nucleic Acid Res Mol Biol 2001;68:41-54.
12. Liu L, Taverna P, Hitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999;5:2908-17.
13. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400.
14. Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW. Human methyl purine DNA glycosylase and DNA polymerase β expression collectively predict sensitivity to temozolomide. Mol Pharmacol 2008;74: 505-16.
15. Horton JK, Wilson SH. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair (Amst) 2003;6:530-43.
16. Hu HY, Horton JK, Gryk MR, et al. Identification of small molecule synthetic inhibitors of DNA polymerase β by NMR chemical shift mapping. J Biol Chem 2004;279:39736-44.
17. Beard WA, Wilson SH. Structure and mechanism of DNA polymerase β. Chem Rev 2006;106:361-82.
18. Narayan S, Jaiswal AS, Balusu R. Tumor suppressor APC blocks DNA polymerase β-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem 2005;280:6942-9.
19. Jaiswal AS, Balusu R, Armas ML, Kundu CN, Narayan S. Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 2006;45:15903-14.
20. Balusu R, Jaiswal AS, Armas ML, Bloom LB, Narayan S. Structure/function analysis of the interaction of adenomatous polyposis coli (APC) with DNA polymerase β and its implications for base excision repair. Biochemistry 2007;46: 13961-74.
21. Kundu CN, Balusu R, Jaiswal AS, Gairola CG, Narayan S. Cigarette smoke condensate-induced levels of adenomatous polyposis coli (APC) block long-patch base excision repair in breast epithelial cells. Oncogene 2007;26: 1428-38.
22. Kundu CN, Balusu R, Jaiswal AS, Narayan S. Adenomatous polyposis colimediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. Carcinogenesis 2007;28:2089-95.
23. Jaiswal AS, Narayan S. A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. Cancer Lett 2008;271:272-80.
24. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7:2309-17.
25. Khan OA, Ranson M, Michael M, et al. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 2008;98:1614-8.
26. Hait WN. Targeted cancer therapies. Cancer Res 2009;69:1263-7.
27. Sawaya MR, Prasad R, Wilson SH, Kraut J, Pelletier H. Crystal structures of human DNA polymerase β complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 1997;36:11205-15.
28. Heyduk T, Lee JC. Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc Natl Acad Sci U S A 1990;87:1744-8.
29. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002;8:2985-91.
30. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
31. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyl-transferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res 1996;56:5375-9.
32. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99.
33. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res 2003;5: 527-32.
34. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993;362: 652-4.
35. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008;14:4859-68.
36. Gschwend DA, Good AC, Kuntz ID. Molecular docking towards drug discovery. J Mol Recognit 1996;9:175-86.
37. Evans SV. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. J Mol Graph 1993;11:134-48.
38. Petrey D, Honig B. GRASP2: visualization, surface properties, and electrostatics of macromolecular structures and sequences. Meth Enzymol 2003;374: 492-509.
39. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001;15:411-28.
40. DeLano WL. The case for open-source software in drug discovery. Drug Discov Today 2005;10:213-7.
41. Prasad R, Beard WA, Wilson SH. Studies of gapped DNA substrate binding by mammalian DNA polymerase β. Dependence on 5′-phosphate group. J Biol Chem 1994;269:18096-101.
42. Izumi T, Malecki J, Chaudhry MA, et al. Intragenic suppression of an active site mutation in the human apurinic/apyrimidinic endonuclease. J Mol Biol 1999; 287:47-57.
43. Izumi T, Mitra S. Deletion analysis of human AP-endonuclease: minimum sequence required for the endonuclease activity. Carcinogenesis 1998;19:525-7.
44. Jaiswal AS, Aneja R, Connors SK, et al. 9-Bromonoscapine-induced mitotic arrest of cigarette smoke condensate-transformed breast epithelial cells. J Cell Biochem 2009;106:1146-56.
45. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;4:225-49.